“The Extraordinary General Meeting of the Shareholders Agenda:
i. The approval for the company Ropharma S.A. to contract a term loan granted by ING Bank NV Amsterdam, Bucharest Branch, to the total amount of 2.000.000 EUR
ii. The approval to guarantee the loans contracted by the company from ING Bank NV Amsterdam, Bucharest Branch, interest, commissions, and costs related, with movable or immovable assets.
iii. The empowerment of the natural persons who shall negotiate the credit conditions and sign the documents in relation to ING Bank.
iv. Establishing the date of December 20 2023 as registration date, according to FSA Regulation no. 5/2018.
v. Establishing the date of December 19 2023 as ex-date, according to FSA Regulation no. 5/2018.
vi. The empowerment of the natural persons who shall fulfill the publicity and registration formalities regarding the General Assembly of Shareholder’s Decisions”, the report reads.
Ropharma has a market capitalization of RON95 million. So far in 2023, its shares have traded 1% lower amid deals worth RON439,000. In the first half of 2023, the company had revenues of RON301 million and a net profit of RON3.5 million.